Semprus BioSciences Names Ulla Wallin Director of Clinical Affairs

Cambridge, MA, January 07, 2011 --(PR.com)-- Semprus BioSciences today announced the appointment of Ulla B. Wallin, BSN, Sc.M., as the company’s first Director of Clinical Affairs. In this role, Ms. Wallin will lead the design and execution of Semprus’ upcoming clinical studies.

Semprus BioSciences is a venture-funded biomedical company designing products to provide patients and clinicians new tools to reduce the 56,000 preventable annual U.S. deaths and $11.2 billion cost of infection- and thrombus-related complications1 that arise when vascular access products are implanted in the body. These technologies include the Semprus Platform, a single-surface modification designed to reduce the attachment of bacteria, fungus, platelets and blood proteins to an implanted medical device. The company spun out of the labs of biomedical researcher and Massachusetts Institute of Technology (MIT) Professor Robert Langer, Sc.D., in 2007.

Immediately prior to joining Semprus, Ms. Wallin served as International Clinical Project Director at NMT Medical, Inc., a Boston-based medical technology company. While at NMT, she oversaw and directed a number of post-market studies evaluating the efficacy of a Class III bio-absorbable structural heart implant.

Ms. Wallin has also held leadership positions with BattelleCRO, Inc., of Newton, MA, where she provided in-depth senior project management oversight on full service clinical projects, and Dover, NH-based TissueLink Medical, Inc., where she planned, developed and implemented clinical feasibility and outcomes studies for 510(k) cleared, novel electrosurgical technology.

“We are delighted to have Ulla onboard to navigate our course through clinical studies for Semprus BioSciences,” said Chief Executive Officer David L. Lucchino. “With twenty years of experience in the planning and execution of domestic and international regulatory submission studies for devices and biopharmaceuticals, Ulla will be an invaluable resource for Semprus, and we eagerly await her guidance and leadership in this critical work on behalf of patients and clinicians.”

Ms. Wallin, a native of Sweden, earned a B.S. in Nursing at Northeastern University and an M.S. in Health Policy Management from Harvard University’s School of Public Health. Prior to arriving in the Boston area, she received a Clinical Specialist Post-Graduate Degree in Intensive Care, OR & Anesthesiology from the University Hospital of Orebro in Orebro, Sweden, and her RN licensure from Sahlgrenska University Hospital in Gothenburg, Sweden.

1 Journal of Wound Care, February 2010 (Wilcott et al.), Chronic Wounds and the Medical Biofilm Paradigm.

###

About Semprus BioSciences
Semprus BioSciences is a venture-backed biomedical company headquartered in Cambridge, Massachusetts. Our innovative, multi-faceted Semprus technology signifies a breakthrough in medical device technology. Our current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device. In December 2010, the company completed an $18 million Series B financing co-led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. Combined with previous financing rounds, Semprus has raised a total of $28.5 million in equity.

Visit http://www.semprusbio.com for additional information.

Contact: Holly P. Glass
holly.glass@semprusbio.com
571.243.1952

Michael Devine
michael.devine@semprusbio.com
617.577.7755 ext. 202